Chemokines in Renal Cell Carcinoma: Implications for Tumor Angiogenesis and Metastasis

2009 ◽  
pp. 249-265
Author(s):  
Karen L. Reckamp ◽  
Robert A. Figlin ◽  
Robert M. Strieter
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Tumor Angiogenesis ◽  
Renal Cell

Abstract B18: CXCL10 suppresses tumor angiogenesis and impedes expression of critical angiogenic factors in renal cell carcinoma

2016 ◽  
Author(s):  
Hyun A Jin ◽  
Jun Hyeok Heo ◽  
You Hyun Kang ◽  
Ki Hong Kim ◽  
Kyung Suk Han ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Tumor Angiogenesis ◽  
Renal Cell ◽  
Angiogenic Factors

scholarly journals YAP Promotes VEGFA Expression and Tumor Angiogenesis Though Gli2 in Human Renal Cell Carcinoma

2019 ◽  
Vol 50 (4) ◽  
pp. 225-233 ◽  
Author(s):  
Shan Xu ◽  
Haibao Zhang ◽  
Yue Chong ◽  
Bing Guan ◽  
Peng Guo
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Tumor Angiogenesis ◽  
Renal Cell ◽  
Human Renal Cell Carcinoma

scholarly journals Progress of Molecular Targeted Therapies for Advanced Renal Cell Carcinoma

2013 ◽  
Vol 2013 ◽  
pp. 1-9 ◽  
Author(s):  
Alessandro Conti ◽  
Matteo Santoni ◽  
Consuelo Amantini ◽  
Luciano Burattini ◽  
Rossana Berardi ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Tumor Angiogenesis ◽  
Targeted Therapies ◽  
Renal Cell ◽  
Mammalian Target Of Rapamycin ◽  
Phosphatidylinositol 3 Kinase ◽  
Von Hippel Lindau ◽  
Angiogenesis Process ◽  
Endothelial Growth Factor

Vascular endothelial growth factor (VEGF) plays a crucial role in tumor angiogenesis. VEGF expression in metastatic renal cell carcinoma (mRCC) is mostly regulated by hypoxia, predominantly via the hypoxia-induced factor (HIF)/Von Hippel-Lindau (VHL) pathway. Advances in our knowledge of VEGF role in tumor angiogenesis, growth, and progression have permitted development of new approaches for the treatment of mRCC, including several agents targeting VEGF and VEGF receptors: tyrosine kinase pathway, serine/threonine kinases,α5β1-integrin, deacetylase, CD70, mammalian target of rapamycin (mTOR), AKT, and phosphatidylinositol 3′-kinase (PI3K). Starting from sorafenib and sunitinib, several targeted therapies have been approved for mRCC treatment, with a long list of agents in course of evaluation, such as tivozanib, cediranib, and VEGF-Trap. Here we illustrate the main steps of tumor angiogenesis process, defining the pertinent therapeutic targets and the efficacy and toxicity profiles of these new promising agents.

229 INHIBITION OF THE GROWTH AND TUMOR ANGIOGENESIS OF RENAL CELL CARCINOMA BY THE STAT3 INHIBITOR WP1066

2011 ◽  
Vol 185 (4S) ◽  
Author(s):  
Akio Horiguchi ◽  
Takako Asano ◽  
Kenji Kuroda ◽  
Akinori Sato ◽  
Junichi Asakuma ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Tumor Angiogenesis ◽  
Renal Cell

scholarly journals MicroRNA‑218 inhibits tumor angiogenesis of human renal cell carcinoma by targeting GAB2

2020 ◽  
Author(s):  
Lijun Mu ◽  
Bing Guan ◽  
Juanhua Tian ◽  
Xiang Li ◽  
Qingzhi Long ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Tumor Angiogenesis ◽  
Renal Cell ◽  
Human Renal Cell Carcinoma

Prognostic Value of Tumor Angiogenesis and Microvascular Invasion in Renal Cell Carcinoma

2006 ◽  
Vol 47 (2) ◽  
pp. 111 ◽  
Author(s):  
Dae Sung Cho ◽  
Hyunee Yim ◽  
Dong Keun Oh ◽  
Jin Hun Kang ◽  
Young Soo Kim ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Tumor Angiogenesis ◽  
Renal Cell ◽  
Prognostic Value ◽  
Microvascular Invasion

Tumor Angiogenesis: A Target for Renal Cell Carcinoma Therapy. Current Perspectives and Novel Strategies

2012 ◽  
Vol 2 (2) ◽  
pp. 99-106
Author(s):  
Matteo Santoni ◽  
Daniele Minardi ◽  
Luciano Burattini ◽  
Rami Raquban ◽  
Stefano Cascinu ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Tumor Angiogenesis ◽  
Renal Cell

scholarly journals Lenvatinib

2018 ◽  
Vol 25 (1) ◽  
pp. 107327481878936 ◽  
Author(s):  
Koichi Suyama ◽  
Hirotaka Iwase
Keyword(s):  
Renal Cell Carcinoma ◽  
Thyroid Cancer ◽  
Growth Factor ◽  
Adverse Events ◽  
Cell Carcinoma ◽  
Tumor Angiogenesis ◽  
Renal Cell ◽  
Growth Factor Receptor ◽  
The United States ◽  
Therapeutic Effects

Lenvatinib is a small-molecule tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor (VEGFR1-3), fibroblast growth factor receptor (FGFR1-4), platelet-derived growth factor receptor α (PDGFRα), stem cell factor receptor (KIT), and rearranged during transfection (RET). These receptors are important for tumor angiogenesis, and lenvatinib inhibits tumor angiogenesis by inhibiting function of these receptors. Phase I trials of lenvatinib were conducted at the same time in Japan, Europe, and the United States, and tumor shrinkage effects were observed in thyroid cancer, endometrial cancer, melanoma, renal cell carcinoma, sarcoma, and colon cancer. Lenvatinib is a promising drug that has shown therapeutic effects against various solid tumors. Adverse events, such as hypertension, proteinuria, diarrhea, and delayed wound healing, can occur with lenvatinib treatment. Managing these adverse events is also important for the use of lenvatinib. In this mini-review article, we outline the current state, toxicity, and future prospects of lenvatinib toward thyroid cancer, hepatocellular carcinoma, renal cell carcinoma, and lung cancer.

Sign in / Sign up

Export Citation Format

Share Document